- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01975103
Non-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases (EPM)
Phase 2 Study of Non-damaging Retinal Laser Therapy Using PASCAL Laser With Endpoint Management Software for Macular Diseases
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Daniel Lavinsky, MD, PhD
- Phone Number: +555133302444
- Email: daniellavinsky@gmail.com
Study Locations
-
-
RS
-
Porto Alegre, RS, Brazil, 90440051
- Recruiting
- Instituto de Oftalmologia Lavinsky
-
Contact:
- Daniel Lavinsky, MD, PhD
- Phone Number: +5551982092999
- Email: daniellavinsky@gmail.com
-
Principal Investigator:
- Daniel Lavinsky, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient must have macular edema involving the center of the macula with a corresponding leakage on fluorescein angiography.
Thickening of the fovea of at least 300 microns (thickness of the central point in OCT) with a standard deviation of the center point <10% and signal strength of ≥ 5 OCT ILM and borders (internal limiting membrane) and RPE (retinal pigment epithelium) properly identified. Also, the initial OCT must be confirmed by repeated measurements on the same day, with the thickness of the central point being within 10% between measurements. In cases where the OCT imaging program can not properly define the limits of ILM and RPE, if the investigator can obtain an estimate of the thickness of the manual by OCT central point of at least 300 microns, the patient will be considered eligible.
The distance visual acuity in the better eye corrected the study must have an index between 70 and 35 letters inclusive (Snellen equivalent of 20/40 to 20/200).
Clear media and eye pupil dilation adequate to allow fundus photography with good quality.
Intraocular pressure not exceeding 21 mmHg. The ophthalmologist should feel comfortable with the delay of the focal laser treatment (direct and grid, as needed) by at least 12 weeks in the study eye.
Patients with diabetes Type I or Type II as defined by WHO criteria of any gender and age ≥ 18 years.
Ability to provide a written consent. Ability to return for all study visits.
Exclusion Criteria:
- Eyes with scatter photocoagulation (PRP) one month prior the enrollment, or eyes where scatter photocoagulation is required now, or it likely to be needed over the next 6months (for example, eyes with high risk PDR DRS not properly treated with photocoagulation).
Presence of any abnormality that is likely to confound the assessment of the improvement in visual acuity in eyes with macular edema to resolve or improve as an area of hard exudates involving the foveal avascular zone (FAZ - involving 2 or more quadrants centered around the foveal avascular zone), epiretinal membrane associated with signs of contraction and / or significant opacification (ie, striations within the diameter of a disc from the center of the fovea), or the presence of chorioretinal atrophy involving the center of the macula.
Vitreomacular traction determined clinically and / or OCT, which in the opinion of the investigator, contributes to macular edema (associated or cause a detachment of the fovea) and prevents the improvement with treatment.
Atrophy / scar / fibrosis involving the center of the macula, including evidence of atrophy treated with laser within 200 microns of the FAZ.
Patients who received panphotocoagulation, YAG laser, or peripheral retinal cryoablation (for retinal tears) or focal or grid photocoagulation within the last 12 weeks or more of treatment with focal or grid laser.
Significant opacities of the optical medium, including cataracts, which may interfere with visual acuity, assessment of toxicity or photography background. Patients will not be included if they have high probability of requiring cataract surgery within the next year.
Any intraocular surgery within 6 months prior to study entry. Prior peeling of epiretinal membrane or inner limiting membrane. Any major surgical procedure within one month of study entry Prior irradiation of the head region of the eye under study. Any previous pharmacological treatment for DME, BRVO, CSR or MacTel (including corticosteroid intravitreal, subconjunctival or subtenon) or at any time during the last 90 days for any other condition.
Important known allergies to sodium fluorescein dye used in angiography. Acute ocular or periocular infection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Topcon Endpoint management
Active laser treatment
|
|
Sham Comparator: Control
Powerless (sham) laser treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Best corrected visual acuity
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Central macular thickness on OCT
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Daniel Lavinsky, MD, PhD, Federal University of Rio Grande do Sul
Publications and helpful links
General Publications
- Lavinsky D, Sramek C, Wang J, Huie P, Dalal R, Mandel Y, Palanker D. Subvisible retinal laser therapy: titration algorithm and tissue response. Retina. 2014 Jan;34(1):87-97. doi: 10.1097/IAE.0b013e3182993edc.
- Lavinsky D, Silva MOD, Chaves AE, Schneider WFM, Lavinsky F, Palanker D. FUNCTIONAL AND STRUCTURAL EFFECTS OF NONDAMAGING RETINAL LASER THERAPY FOR MACULAR TELANGIECTASIA TYPE 2: A Randomized Sham-Controlled Clinical Trial. Retina. 2021 Mar 1;41(3):487-494. doi: 10.1097/IAE.0000000000002882.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EPM-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Macular Edema
-
OcugenNot yet recruitingDiabetic Macular Edema | Center Involved Diabetic Macular Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
OculisICON plcRecruitingDiabetic Macular EdemaUnited States
-
Novartis PharmaceuticalsNot yet recruiting
-
Vista KlinikNot yet recruitingDiabetic Macular Edema
-
Chinese University of Hong KongRecruiting
-
Laboratorios Sophia S.A de C.V.RecruitingDiabetic Macular EdemaColombia, Mexico
-
Centre Hospitalier Universitaire DijonRecruiting
-
Uptown Eye SpecialistsNot yet recruitingDiabetic Macular Edema
-
Hospices Civils de LyonRecruiting
Clinical Trials on Topcon Endpoint Management
-
Retinal Consultants of ArizonaTopcon CorporationCompleted
-
Topcon Medical Systems, Inc.CompletedIntraocular PressureUnited States
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited States, Canada, Ukraine, Spain, United Kingdom, New Zealand, Netherlands, Bulgaria, Norway, Denmark, Czech Republic, Slovenia
-
Ospedale San RaffaeleUniversity of Rome Tor Vergata; University of Genova; Fondazione G.B. Bietti,...RecruitingMacular Degeneration, Dry | Macular Degeneration, Senile | Laser Burn of Retina | Macular Degeneration IntermediateItaly
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Shaare Zedek Medical CenterUnknownCarotid Stenosis | Carotid Endarterectomy | Choroid
-
Assiut UniversityNot yet recruiting
-
University of SaskatchewanCompleted
-
Topcon Medical Systems, Inc.CompletedMedical Need for Fluorescein Angiography ImagingUnited States